WhilediABZI and other STING agonists are currently under clinicalinvestigation (e.g., NCT03843359, NCT04420884, and NCT04609579), theylack tumor or cell specificity, and concerns exist regarding the consequencesof indiscriminate systemic STING activation. This evidence concerns the gene STING1 and neoplasm.